Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Plans Percutaneous Valve Trials For European, U.S. Market Approval

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' percutaneous aortic valve PMA submission likely will include a randomized trial with 12-month follow-up

You may also be interested in...



CoreValve Expands Percutaneous Aortic Valve Trial In Europe

CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end

CoreValve Expands Percutaneous Aortic Valve Trial In Europe

CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end

Percutaneous Aortic Valve IDE Approval Rests On Clearer Criteria – Edwards

Edwards Lifesciences will work with FDA on crafting an acceptable definition for "high-risk patients" to meet an investigational device exemption approval goal of early 2005 for its percutaneous aortic valve, the firm said in a Dec. 3 investor conference

Related Content

UsernamePublicRestriction

Register

MT020145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel